Citicoline in addictive disorders: a review of the literature

References

• Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593–602
   PubMed Web of Science ®Google Scholar
• Annual Report 2012. University T.N.C.o.A.a.S.A.a.C., ed., 2012
   Google Scholar
• Drug Abuse and Addiction. Available from: http://www.drugabuse.gov/sites/default/files/addictionscience.ppt: NIDA; 2011
   Google Scholar
• van den Brink W. Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Curr Drug Abuse Rev 2012;5:3–31
   PubMedGoogle Scholar
• D’Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurolog Res 1995;17:281–284
   PubMed Web of Science ®Google Scholar
• Silveri MM, Dikan J, Ross AJ, Jensen JE, Kamiya T, Kawada Y, Renshaw PF, Yurgelun-Todd DA. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed 2008;21:1066–1075
   PubMed Web of Science ®Google Scholar
• Tayebati SK, Amenta F. Choline-containing phospholipids: relevance to brain functional pathways. Clin Chem Lab Med/FESCC 2013;51:513–521
   PubMed Web of Science ®Google Scholar
• Arenth PM, Russell KC, Ricker JH, Zafonte RD. CDP-choline as a biological supplement during neurorecovery: a focused review. Phys Med Rehabilit 2011;3:S123–S131
   Google Scholar
• de la Morena E. Efficacy of CDP-choline in the treatment of senile alterations in memory. Ann NY Acad Sci 1991;640:233–236
   Google Scholar
• Thorne Research I. Citicoline. Alt Med Rev 2008;13:50–75
   Google Scholar
• Adibhatla RM, Hatcher JF. Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res 2005;30:15–23
   PubMed Web of Science ®Google Scholar
• Agut J, Ortiz JA, Wurtman RJ. Cytidine (5′)diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by microdialysis. Ann NY Acad Sci 2000;920:332–335
   Google Scholar
• Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Meth Findings Experim Clin Pharmacol 1995;17:1–54
   PubMed Web of Science ®Google Scholar
• Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Systematic Rev 2005;Apr 18:CD000269
   Google Scholar
• Fioravanti M, Buckley AE. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Intervent Aging 2006;1:247–251
   PubMed Web of Science ®Google Scholar
• Hurtado O, Moro MA, Cardenas A, Sanchez V, Fernandez-Tome P, Leza JC, Lorenzo P, et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol Dis 2005;18:336–345
   PubMed Web of Science ®Google Scholar
• Martinet M, Fonlupt P, Pacheco H. Effects of cytidine-5′ diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Arch Int Pharmacodyn Ther 1979;239:52–61
   PubMedGoogle Scholar
• Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ. Citicoline improves verbal memory in aging. Arch Neurol 1996;53:441–448
   PubMed Web of Science ®Google Scholar
• Zafonte RD, Bagiella E, Ansel BM, Novack TA, Friedewald WT, Hesdorffer DC, Timmons SD, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA 2012;308:1993–2000
   PubMed Web of Science ®Google Scholar
• Alvarez-Sabin J, Maisterra O, Santamarina E, Kase CS. Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurol 2013;12:689–705
   PubMed Web of Science ®Google Scholar
• Davalos A, Alvarez-Sabin J, Castillo J, Diez-Tejedor E, Ferro J, Martinez-Vila E, Serena J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012;380:349–357
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Meth Findings Experim Clin Pharmacol 2009;31:171–176
   PubMedGoogle Scholar
• Richardson J, Murray D, House CK, Lowenkopf T. Successful implementation of the National Institutes of Health Stroke Scale on a stroke/neurovascular unit. J Neurosci Nursing 2006;38:309–315
   PubMedGoogle Scholar
• Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Maryland State Med J 1965;14:61–65
   PubMedGoogle Scholar
• Lukas SE, Kouri EM, Rhee C, Madrid A, Renshaw PF. Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects. Psychopharmacology 2001;157:163–167
   Google Scholar
• Renshaw PF, Daniels S, Lundahl LH, Rogers V, Lukas SE. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology 1999;142:132–138
   Google Scholar
• Licata SC, Penetar DM, Ravichandran C, Rodolico J, Palmer C, Berko J, Geaghan T, et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addiction Med 2011;5:57–64
   Google Scholar
• Bracken BK, Penetar DM, Rodolico J, Ryan ET, Lukas SE. Eight weeks of citicoline treatment does not perturb sleep/wake cycles in cocaine-dependent adults. Pharmacol, Biochem Behav 2011;98:518–524
   Google Scholar
• Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 2007;27:498–502
   PubMed Web of Science ®Google Scholar
• Yoon SJ, Lyoo IK, Kim HJ, Kim TS, Sung YH, Kim N, Lukas SE, Renshaw PF. Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5′-diphosphate choline: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2010;35:1165–1173
   PubMed Web of Science ®Google Scholar
• Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Progress Neurobiol 1995;46:531–540
   PubMed Web of Science ®Google Scholar
• Brown ES, Gabrielson B. A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affective Disord 2012;143:257–260
   PubMed Web of Science ®Google Scholar
• Chinchilla A, Lopez-Ibor M, Vegay M. Camarero. CDP-coline in the evolution of mental functions in alcohol withdrawal syndrome. Psiquiatria Biologica 1995;2:171–175
   Google Scholar
• Killgore WD, Ross AJ, Kamiya T, Kawada Y, Renshaw PF, Yurgelun-Todd DA. Citicoline affects appetite and cortico-limbic responses to images of high-calorie foods. Int J Eating Disord 2010;43:6–13
   Google Scholar
• Lozano Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittel-Forschung 1983;33:1073–1080
   Google Scholar
• Alvarez XA, Sampedro C, Lozano R, Cacabelos R. Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats. Meth Findings Experim Clin Pharmacol 1999;21:535–540
   PubMed Web of Science ®Google Scholar
• Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Annals Neurol 2000;48:713–722
   PubMed Web of Science ®Google Scholar
• Parisi V, Coppola G, Centofanti M, Oddone F, Angrisani AM, Ziccardi L, Ricci B, et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Progress Brain Res 2008;173:541–554
   PubMed Web of Science ®Google Scholar
• Williams MJ, Adinoff B. The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 2008;33:1779–1797
   PubMed Web of Science ®Google Scholar
• Hoebel BG, Avena NM, Rada P. Accumbens dopamine-acetylcholine balance in approach and avoidance. Curr Opin Pharmacol 2007;7:617–627
   PubMed Web of Science ®Google Scholar
• Mark GP, Shabani S, Dobbs LK, Hansen ST. Cholinergic modulation of mesolimbic dopamine function and reward. Physiol Behav 2011;104:76–81
   PubMed Web of Science ®Google Scholar
• Zhang W, Yamada M, Gomeza J, Basile AS, Wess J. Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J Neurosci 2002;22:6347–6352
   PubMed Web of Science ®Google Scholar
• Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005;162:1414–1422
   PubMed Web of Science ®Google Scholar
• Apicella P, Ravel S, Deffains M, Legallet E. The role of striatal tonically active neurons in reward prediction error signaling during instrumental task performance. J Neurosci 2011;31:1507–1515
   Google Scholar
• Imperato A, Obinu MC, Gessa GL. Effects of cocaine and amphetamine on acetylcholine release in the hippocampus and caudate nucleus. Eur J Pharmacol 1993;238:377–381
   PubMed Web of Science ®Google Scholar
• Caamano J, Gomez MJ, Franco A, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Meth Findings Experim Clin Pharmacol 1994;16:211–218
   Google Scholar
• Cockrell JR, Folstein MF. Mini-Mental State Examination (MMSE). Psychopharmacol Bull 1988;24:689–692
   PubMed Web of Science ®Google Scholar
• Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernandez M, Diez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurological Sciences 2010;299:188–192
   PubMed Web of Science ®Google Scholar
• Babb SM, Wald LL, Cohen BM, Villafuerte RA, Gruber SA, Yurgelun-Todd DA, Renshaw PF. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology 2002;161:248–254
   PubMed Web of Science ®Google Scholar
• Adinoff B, Rilling LM, Williams MJ, Schreffler E, Schepis TS, Rosvall T, Rao U. Impulsivity, neural deficits, and the addictions: the “oops” factor in relapse. J Addictive Dis 2007;26:25–39
   PubMedGoogle Scholar
• Kosten TR. Pharmacotherapy of cerebral ischemia in cocaine dependence. Drug Alcohol Depend 1998;49:133–144
   PubMed Web of Science ®Google Scholar
• Matyja E, Taraszewska A, Naganska E, Grieb P, Rafalowska J. CDP-choline protects motor neurons against apoptotic changes in a model of chronic glutamate excitotoxicity in vitro. Folia Neuropathologica 2008;46:139–148
   PubMed Web of Science ®Google Scholar
• Mir C, Clotet J, Aledo R, Durany N, Argemi J, Lozano R, Cervos-Navarro J, Casals N. CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. J Molec Neurosci 2003;20:53–60
   PubMedGoogle Scholar
• Uys JD, LaLumiere RT. Glutamate: the new frontier in pharmacotherapy for cocaine addiction. CNS Neurolog Disord Drug Targets 2008;7:482–491
   PubMed Web of Science ®Google Scholar